Latest Hodgkin's lymphoma Stories
Anti-CD20-Interferon Alpha Fusion Protein (IGN002) is a promising drug candidate for NHL patients who are resistant to standard therapy WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6( )million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change...
- Pricing Negotiations to Begin in June - SEATTLE, May 20, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for PIXUVRI® (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy. The G-BA reported that additional benefit...
INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new...
Firm’s Senior Manager of Corporate Social Responsibility among 20 D.C.-area candidates aiming to raise $1.2 million for LLS National Capital Chapter in just 10 weeks. McLean, Virginia (PRWEB) May 06, 2013 MorganFranklin Consulting, a leading business consulting and technology solutions company based in McLean, Va., and London, announced today that Jeana Foster, the firm’s Senior Manager of Corporate Social Responsibility (CSR), has been named a candidate in the Leukemia & Lymphoma...
MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor. The US-based study is an...
Faster approvals needed for coverage by provincial drug plans: Lymphoma Foundation Canada TORONTO, April 24, 2013 /CNW/ - The recent approval by Health Canada of a highly effective new treatment for non-Hodgkin lymphoma and the subsequent decision by several provinces to cover the cost for cancer patients is very good news, says Lymphoma Foundation Canada (LFC). However, the organization says more must be done to speed up the coverage by provincial drug plans for a host of...
Voices Against Brain Cancer (VABC), the organization dedicated to brain cancer research and advocacy, responds to an article published on biosciencetechnology.com that examines a Phase 2 clinical trial study focusing on a new brain cancer treatment. New York, NY (PRWEB) April 22, 2013 On April 22, Voices Against Brain Cancer (VABC), an organization dedicated to brain cancer research and advocacy, comments on an article published by Biosciencetechnology.com that discusses a new Phase 2...
SEATTLE, April 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). The draft guidance does...
Despite comparable pre-surgery risk scores, patients with radiation heart disease found to be at much greater risk years after surgery Patients who have open heart surgery for heart disease caused by radiation cancer treatment are nearly twice as likely to die in the years following their surgery compared to similar patients who did not undergo radiation treatment, according to new research from Cleveland Clinic published today in the American Heart Association journal Circulation. The...
Designation granted in the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with a genetic mutation, del17p RARITAN, N.J., April 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted a third Breakthrough Therapy Designation for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. Ibrutinib has been granted Breakthrough...
